Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors

This study investigates the effects of a site-directed TG2-selective inhibitor on the lung myofibroblast phenotype and ECM deposition to elucidate TG2 as a novel therapeutic target in idiopathic pulmonary fibrosis (IPF)—an incurable progressive fibrotic disease. IPF fibroblasts showed increased expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Fell, Shaun, Wang, Zhuo, Blanchard, Andy, Nanthakumar, Carmel, Griffin, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910249/
https://www.ncbi.nlm.nih.gov/pubmed/33474654
http://dx.doi.org/10.1007/s00726-020-02938-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910249/
https://www.ncbi.nlm.nih.gov/pubmed/33474654
http://dx.doi.org/10.1007/s00726-020-02938-w

Ejemplares similares